EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Disproportionality Analysis and Timing of Drug-Associated Guillain–Barré Syndrome Onset Based on the Japanese Adverse Drug Event Report Database

Shinya Toriumi iD, Yousuke Kurihara, Komei Shimokawa, Arihito Tanaka, Norito Araki, Osamu Kawai, Yasoo Sugiura iD, Yoshihiro Uesawa iD

Pharmaceuticals · 28.04.2026 · 19 (5) · 688

DOI: 10.3390/ph19050688 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmaceuticals, online erschienen am 28.04.2026. Verfasst von Shinya Toriumi und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Molecular Informatics, Meiji Pharmaceutical University, Kiyose 204-8588, Tokyo, Japan. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 108 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Guillain–Barré syndrome (GBS) is an autoimmune peripheral neuropathy that can lead to paralysis and respiratory failure. In addition to infections, several drugs have been suggested as potential triggers of GBS. This study investigated drug-associated GBS using a spontaneous adverse event reporting database through disproportionality analysis for signal detection and time-to-onset analysis.

Methods

The Japanese Adverse Drug Event Report (JADER) database was analyzed to assess more than 4000 drugs for potential associations with GBS. Signal detection was performed using reporting odds ratios, Fisher’s exact test, and total report counts. For vaccines and immune checkpoint inhibitors, time-to-onset patterns were further evaluated using Weibull distribution analysis.

Results

Disproportionality signals suggesting potential associations with GBS were identified for 45 drugs, including vaccines, immune checkpoint inhibitors, tumor necrosis factor-α inhibitors, other anticancer drugs, antifungal agents, and interferons. Reports following vaccination were most frequently observed within 1–3 weeks after administration of coronavirus disease 2019 (COVID-19), influenza, and pneumococcal vaccines, and within 1–3 months after human papillomavirus 2-valent vaccination, with a gradual decrease thereafter. Reports following immune checkpoint inhibitor use were most frequently observed 1–3 months after nivolumab, ipilimumab, and pembrolizumab administration, whereas atezolizumab showed a peak in reporting within 1–3 weeks. In contrast to vaccine-related reports, no clear temporal trend in reporting was observed.

Conclusions

Drugs that modulate immune function, including vaccines and immune checkpoint inhibitors, may be associated with reported GBS events. Vaccine-related reports showed an early concentration in time to onset, whereas immune checkpoint inhibitor-related reports did not demonstrate a clear temporal pattern. These findings should be interpreted as hypothesis-generating and warrant further investigation.

Schlagwörter

Stichwörter der Autor:innen

Guillain–Barré syndromeJapanese adverse drug event report databaseWeibull distributionacute inflammatory demyelinating polyneuropathydisproportionality analysisimmune checkpoint inhibitorspharmacovigilancespontaneous reporting systemtime-to-onset analysisvaccines

Autor:innen und Institutionen

  • Department of Medical Molecular Informatics, Meiji Pharmaceutical University, Kiyose 204-8588, Tokyo, Japan.
  • Department of Pharmacy, National Hospital Organization Kanagawa Hospital, Hadano 257-8585, Kanagawa, Japan.
  • Department of Respiratory Medicine, National Hospital Organization Kanagawa Hospital, Hadano 257-8585, Kanagawa, Japan.
  • Department of General Thoracic Surgery, National Hospital Organization Saitama Hospital, Wako 351-0102, Saitama, Japan.

ORCID-Profile: Shinya Toriumi, Yasoo Sugiura, Yoshihiro Uesawa

Förderung

  • Japan Society for the Promotion of Science

Zitieren

APA

Toriumi, S., Kurihara, Y., Shimokawa, K., Tanaka, A., Araki, N., Kawai, O., Sugiura, Y., & Uesawa, Y. (2026). Disproportionality Analysis and Timing of Drug-Associated Guillain–Barré Syndrome Onset Based on the Japanese Adverse Drug Event Report Database. Pharmaceuticals, 19(5), 688. https://doi.org/10.3390/ph19050688

Vancouver

Toriumi S, Kurihara Y, Shimokawa K, Tanaka A, Araki N, Kawai O, et al. Disproportionality Analysis and Timing of Drug-Associated Guillain–Barré Syndrome Onset Based on the Japanese Adverse Drug Event Report Database. Pharmaceuticals. 2026;19(5):688. doi:10.3390/ph19050688

BibTeX
@article{Toriumi2026,
  author = {Toriumi, Shinya and Kurihara, Yousuke and Shimokawa, Komei and Tanaka, Arihito and Araki, Norito and Kawai, Osamu and Sugiura, Yasoo and Uesawa, Yoshihiro},
  title = {Disproportionality Analysis and Timing of Drug-Associated Guillain–Barré Syndrome Onset Based on the Japanese Adverse Drug Event Report Database},
  journal = {Pharmaceuticals},
  year = {2026},
  volume = {19},
  number = {5},
  pages = {688},
  doi = {10.3390/ph19050688}
}
Kostenlos starten →